Department of Chemical and Biomolecular Engineering
College of Engineering
University of Nebraska–Lincoln
207N Othmer Hall
Lincoln, Nebraska 68588-0643 United States
kvancott2@unl.edu
Research interests may be described using the phrase "functional proteomics," but with a twist. In this case, the object is not looking at thousands of different proteins that cells are producing. Instead, our research is looking at recombinant proteins that are produced in bioreactors. These proteins are very complex because they have numerous post-translational modifications (PTMs); that is, chemical modifications made to the amino acid side chains, such as glycosylation, gamma-carboxylation, phosphorylation, sulfation, and proteolytic processing. Thus, in the lab a "pure" protein can have many different subpopulations that differ in the nature and/or extent of their modification. The objective of this research is to characterize the structure of these subpopulations and then relate the structure to the in vivo function and pharmacokinetic properties. This work requires expertise in protein purification and analytical biochemistry, which is carried out in a Protein Characterization Laboratory (PCL), part of the Biological Process Development Facility at UNL. HPLC, SDS PAGE methods, enzymatic assays, peptide mapping, and LC-MS-MS are routinely used as tools for this work. Presently being used is an Applied Biosystems 4000 QTrap MS instrument for these molecules. This MS instrument has been invaluable in helping us discern the PTMs on the proteins.
2021
ENGINEERED CLOSTRIDIUM BOTULINUM TOXIN ADAPTED TO DELIVER MOLECULES INTO SELECTED CELLS, Benjamin J. Pavlik, Paul Blum, and Kevin Van Cott
2020
ENGINEERED CLOSTRIDIUM BOTULINUM TOXIN ADAPTED TO DELIVER MOLECULES INTO SELECTED CELLS, Benjamin J. Pavlik, Paul Blum, and Kevin Van Cott
ENGINEERED CLOSTRIDIUM BOTULINUM TOXIN ADAPTED TO DELIVER MOLECULES INTO SELECTED CELLS, Benjamin J. Pavlik, Paul H. Blum, and Kevin Van Cott
2016
Characterization of IXINITY (Trenonacog Alfa), a Recombinant Factor IX with Primary Sequence Corresponding to the Threonine-148 Polymorph, Dougald M. Monroe, Richard J. Jenny, Kevin E. Van Cott, Shelly Buhay, and Laura L. Saward
Retargeting the Clostridium botulinum C2 toxin to the neuronal cytosol, Benjamin J. Pavlik, Elizabeth J. Hruska, Kevin E. Van Cott, and Paul H. Blum
2011
Process Development and cGMP Manufacturing of a Recombinant Ricin Vaccine: an Effective and Stable Recombinant Ricin A-Chain Vaccine—RVEcTM, Michael M. Meagher, Javier G. Seravalli, S. Todd Swanson, Roger G. Ladd, Yogender P. Khasa, Mehmet Inan, Jay C. Harner, Scott K. Johnson, Kevin E. Van Cott, Changhong Lindsey, Robert Wannemacher, and Leonard A. Smith
2010
High throughput quantification of N-glycans using one-pot sialic acid modification and matrix assisted laser desorption ionization time of flight mass spectrometry, Geun-Cheol Gil, Bryce Iliff, Ron Cerny, William H. Velander, and Kevin E. Van Cott
2009
N-glycosylation Microheterogeneity and Site Occupancy of an Asn-X-Cys Sequon in Plasma-derived and Recombinant Protein C, Geun-Cheol Gil, William H. Velander, and Kevin E. Van Cott
2008
Analysis of the N-glycans of recombinant human Factor IX purified from transgenic pig milk, Geun-Cheol Gil, William H. Velander, and Kevin E. Van Cott
2005
POLAR ORDERING OF REACTIVE CHROMOPHORES IN LAYER-BY-LAYER NONLINEAR OPTICAL MATERIALS, Kevin Van Cott, James R. Heflin Jr., Harry Gibson, and Richey M. Davis
cGMP Recombinant FIX for IV and Oral Hemophilia B Therapy, William H. Velander PRINCIPAL INVESTIGATOR, Abramson Stephan LEAD INVESTIGATOR, Cooper Julian LEAD INVESTIGATOR, William Dernell KEY PERSON, Mark Manning LEAD INVESTIGATOR, Michael Meagher LEAD INVESTIGATOR, Paul Mohanan LEAD INVESTIGATOR, Timothy Nichols LEAD INVESTIGATOR, Todd Swaanson KEY PERSON, and Kevin E. Van Cott
2004
Haemophilic Factors Produced by Transgenic Livestock: Abundance that can enable alternative therapies worldwide, Kevin E. Van Cott, Paul E. Monahan, Timothy C. Nichols, and William H. Velander
1999
Inside-out crosslinked and commercial-scale hydrogels, and sub-macromolecular selective purification using the hyrdogels, William H. Velander and Kevin E. Van Cott
1996
Affinity Purification of Biologically Active andInactive Forms of Recombinant Human Protein C Produced in Porcine Mammary Gland, Kevin E. Van Cott; Barry Williams Department of Chemical Engineering,Virginia Tech University, Blacksburg, VA 24061, USA; William H. Velander; Francis C. Gwazdauskas; Tim Lee Jerome Holland Laboratory, American Red Cross, Rockville, MD 20855, USA; Henryk Lubon; and William N. Drohan